Eli Lilly Launches Oral GLP-1 Medication Orforglipron for Weight Loss in the United States

Eli Lilly and Company announced the US launch of Foundayo, the branded version of orforglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. The medication is indicated for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia.

Orforglipron was approved by the US Food and Drug Administration in late 2023 following clinical trials demonstrating its efficacy in reducing body weight.

The drug represents Eli Lilly's entry into the oral segment of the GLP-1 market, which has been dominated by injectable options like semaglutide and tirzepatide. Foundayo is administered as a once-daily pill, potentially improving patient adherence compared to injections.

According to @LiveSquawk, the launch makes the medication available at pharmacies nationwide, with initial pricing set at approximately $1,000 per month before insurance adjustments.

orforglipron involved over 3,000 participants and showed average weight loss of 14-15% over 72 weeks when combined with diet and exercise.

The studies, published in the New England Journal of Medicine, reported common side effects including nausea, diarrhea, and vomiting, similar to other GLP-1 drugs. Eli Lilly reported positive topline results in phase 3 trials in 2023, paving the way for regulatory submission.

The obesity treatment landscape includes an estimated 42% of US adults classified as obese, according to Centers for Disease Control and Prevention data.

GLP-1 agonists work by mimicking hormones that regulate appetite and blood sugar. Foundayo's oral formulation addresses a key barrier for patients averse to needles, potentially expanding access to pharmacotherapy.